The 19% functional cure rate is statistically significant and clinically meaningful, but the real story is what happens beyond that headline number. An exploratory analysis found 49% of bepirovirsen recipients hit a surface antigen level linked to stronger immune control a year after treatment ended. Surface antigen loss is tied to an 89% reduction in liver cancer risk — that's the kind of outcome that redefines what treating hepatitis B can look like.